Brokerages Expect Y-mAbs Therapeutics, Inc (YMAB) to Post -$0.33 EPS

Brokerages predict that Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) will report ($0.33) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Y-mAbs Therapeutics’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.36). The firm is scheduled to issue its next quarterly earnings report on Tuesday, February 12th.

On average, analysts expect that Y-mAbs Therapeutics will report full year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.44) to ($1.38). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.49) to ($1.25). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Y-mAbs Therapeutics.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Tuesday, November 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09).

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Sunday, January 6th. Bank of America assumed coverage on shares of Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They set a “buy” rating and a $26.00 target price on the stock. Canaccord Genuity assumed coverage on shares of Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They set a “buy” rating and a $30.00 target price on the stock. Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Tuesday, October 16th. Finally, BTIG Research assumed coverage on shares of Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They set a “buy” rating and a $35.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, Y-mAbs Therapeutics currently has an average rating of “Buy” and a consensus price target of $28.50.

Institutional investors and hedge funds have recently made changes to their positions in the company. Citigroup Inc. purchased a new position in Y-mAbs Therapeutics during the 4th quarter valued at about $37,000. Strs Ohio purchased a new position in Y-mAbs Therapeutics during the 4th quarter valued at about $38,000. Point72 Asset Management L.P. purchased a new position in Y-mAbs Therapeutics during the 3rd quarter valued at about $133,000. GSA Capital Partners LLP purchased a new position in Y-mAbs Therapeutics during the 3rd quarter valued at about $266,000. Finally, Laurion Capital Management LP purchased a new position in Y-mAbs Therapeutics during the 3rd quarter valued at about $398,000. 22.38% of the stock is currently owned by hedge funds and other institutional investors.

Shares of YMAB opened at $21.72 on Friday. Y-mAbs Therapeutics has a 1-year low of $15.17 and a 1-year high of $31.00.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Read More: What are the advantages of the Stochastic Momentum Index?

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply